Zevra CMO to Depart in Planned Transition, Will Consult Through Year-End
ZVRA sits 89% above its 52-week low of $7.16 on elevated volume (1.9× avg).
Summary
Zevra Therapeutics announced its Chief Medical Officer, Adrian Quartel, will step down for personal reasons, effective July 3, 2026. Dr. Quartel will remain as a consultant through year-end to ensure a seamless transition, and the company is actively searching for a replacement. This follows Zevra's strong Q1 2026 results, which included significant revenue growth and net income. While presented as a planned transition, the departure of a CMO is notable for a commercial-stage biotech company with an active pipeline, as this role is crucial for clinical development and regulatory strategy. Zevra affirmed its regulatory milestones remain on track, including an MAA for arimoclomol and a Phase 3 trial for celiprolol.
At the time of this announcement, ZVRA was trading at $13.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $798.1M. The 52-week trading range was $7.16 to $14.27. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.